Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes
Background Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to inves...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.017086 |
| _version_ | 1818775917197000704 |
|---|---|
| author | Willy Weng Christiane Wiefels Santabhanu Chakrabarti Pablo B. Nery Emel Celiker-Guler Jeff S. Healey Tomasz W. Hruczkowski F. Russell Quinn Steven Promislow Maria C. Medor Stewart Spence Roupen Odabashian Wael Alqarawi Daniel Juneau Rob de Kemp Eugene Leung Rob Beanlands David Birnie |
| author_facet | Willy Weng Christiane Wiefels Santabhanu Chakrabarti Pablo B. Nery Emel Celiker-Guler Jeff S. Healey Tomasz W. Hruczkowski F. Russell Quinn Steven Promislow Maria C. Medor Stewart Spence Roupen Odabashian Wael Alqarawi Daniel Juneau Rob de Kemp Eugene Leung Rob Beanlands David Birnie |
| author_sort | Willy Weng |
| collection | DOAJ |
| description | Background Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to investigate AA incidence, burden, predictors, and response to immunosuppression. Methods and Results This project is a substudy of the CHASM‐CS (Cardiac Sarcoidosis Multicenter Prospective Cohort Study; NCT01477359). Inclusion criteria were presentation with clinically manifest cardiac sarcoidosis, treatment‐naive status, and implanted with a device that reported accurate AA burden. Data were collected at each device interrogation visit for all patients and all potential episodes of AA were adjudicated. For each intervisit period, the total AA burden was obtained. A total of 33 patients met the inclusion criteria (aged 56.1±7.7 years, 45.5% women). Only 1 patient had important AAs as a part of the initial CS presentation. During a median follow‐up of 49.1 months, 11 of 33 patients (33.3%) had device‐detected AAs, and only 2 (6.1%) had a clinically significant AA burden. Both patients had reduced burden after CS was successfully treated and there was no residual fluorodeoxyglucose uptake on positron emission tomography scan. Conclusions First, we found that AAs are a rare presenting feature of clinically manifest cardiac sarcoidosis. Second, AAs occurred in a minority of patients at follow‐up; the burden was very low in most patients. Only 2 patients had clinically significant AA burden, and both had a reduction after CS was treated. Registration URL: https://www.clinicaltrials.gov; unique identifier NCT01477359. |
| first_indexed | 2024-12-18T11:04:39Z |
| format | Article |
| id | doaj.art-2def3554e2fe41099489c87436790ef3 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-18T11:04:39Z |
| publishDate | 2020-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-2def3554e2fe41099489c87436790ef32022-12-21T21:10:09ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802020-09-0191710.1161/JAHA.120.017086Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and OutcomesWilly Weng0Christiane Wiefels1Santabhanu Chakrabarti2Pablo B. Nery3Emel Celiker-Guler4Jeff S. Healey5Tomasz W. Hruczkowski6F. Russell Quinn7Steven Promislow8Maria C. Medor9Stewart Spence10Roupen Odabashian11Wael Alqarawi12Daniel Juneau13Rob de Kemp14Eugene Leung15Rob Beanlands16David Birnie17Division of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of British Columbia Vancouver BC CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaPopulation Health Research Institute McMaster University Hamilton ON CanadaMazankowski Alberta Heart Institute University of Alberta Edmonton AB CanadaLibin Cardiovascular Institute of Alberta Calgary AB CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaDivision of Cardiology University of Ottawa Heart Institute Ottawa ON CanadaBackground Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to investigate AA incidence, burden, predictors, and response to immunosuppression. Methods and Results This project is a substudy of the CHASM‐CS (Cardiac Sarcoidosis Multicenter Prospective Cohort Study; NCT01477359). Inclusion criteria were presentation with clinically manifest cardiac sarcoidosis, treatment‐naive status, and implanted with a device that reported accurate AA burden. Data were collected at each device interrogation visit for all patients and all potential episodes of AA were adjudicated. For each intervisit period, the total AA burden was obtained. A total of 33 patients met the inclusion criteria (aged 56.1±7.7 years, 45.5% women). Only 1 patient had important AAs as a part of the initial CS presentation. During a median follow‐up of 49.1 months, 11 of 33 patients (33.3%) had device‐detected AAs, and only 2 (6.1%) had a clinically significant AA burden. Both patients had reduced burden after CS was successfully treated and there was no residual fluorodeoxyglucose uptake on positron emission tomography scan. Conclusions First, we found that AAs are a rare presenting feature of clinically manifest cardiac sarcoidosis. Second, AAs occurred in a minority of patients at follow‐up; the burden was very low in most patients. Only 2 patients had clinically significant AA burden, and both had a reduction after CS was treated. Registration URL: https://www.clinicaltrials.gov; unique identifier NCT01477359.https://www.ahajournals.org/doi/10.1161/JAHA.120.017086atrial arrhythmiaatrial fibrillationcardiac sarcoidosis |
| spellingShingle | Willy Weng Christiane Wiefels Santabhanu Chakrabarti Pablo B. Nery Emel Celiker-Guler Jeff S. Healey Tomasz W. Hruczkowski F. Russell Quinn Steven Promislow Maria C. Medor Stewart Spence Roupen Odabashian Wael Alqarawi Daniel Juneau Rob de Kemp Eugene Leung Rob Beanlands David Birnie Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease atrial arrhythmia atrial fibrillation cardiac sarcoidosis |
| title | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
| title_full | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
| title_fullStr | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
| title_full_unstemmed | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
| title_short | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
| title_sort | atrial arrhythmias in clinically manifest cardiac sarcoidosis incidence burden predictors and outcomes |
| topic | atrial arrhythmia atrial fibrillation cardiac sarcoidosis |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.120.017086 |
| work_keys_str_mv | AT willyweng atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT christianewiefels atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT santabhanuchakrabarti atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT pablobnery atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT emelcelikerguler atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT jeffshealey atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT tomaszwhruczkowski atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT frussellquinn atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT stevenpromislow atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT mariacmedor atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT stewartspence atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT roupenodabashian atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT waelalqarawi atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT danieljuneau atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT robdekemp atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT eugeneleung atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT robbeanlands atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT davidbirnie atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes |